GS-4571
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 22, 2026
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
(clinicaltrials.gov)
- P1 | N=134 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: Jul 2026 ➔ Nov 2026 | Trial primary completion date: Jul 2026 ➔ Nov 2026
Trial completion date • Trial primary completion date • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
September 21, 2024
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
(clinicaltrials.gov)
- P1 | N=134 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting
Enrollment open • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
August 20, 2024
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
(clinicaltrials.gov)
- P1 | N=134 | Not yet recruiting | Sponsor: Gilead Sciences
New P1 trial • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
1 to 3
Of
3
Go to page
1